Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to define the maximum tolerated dose of combination docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects will be measured in study participants. In addition, researchers will assess data about preliminary efficacy in patients with this treatment approach.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tony Bekaii-Saab
• Collaborators: University of Michigan Cancer Center; University of Michigan Rogel Cancer Center
• Treatments: Capecitabine; Docetaxel; Gemcitabine; Pancrelipase

Criteria

Inclusion Criteria:

• adenocarcinoma of the pancreas

• no prior chemo except adjuvant

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

• peripheral neuropathy Exclusion Criteria:

• Pregnant/lactating females

• Uncontrolled heart disease, diabetes, psychiatric disorder

• Therapeutic doses of Warfarin